The Indian company says it has offered 7% royalty to the US drugmaker for Baricitinib. Natco has filed for compulsory licensing, arguing that Eli Lilly’s small distribution network won’t be able to serve India’s population and the 14-day, Rs 42,000 per-patient treatment regimen for the US drug is too expensive.How Natco Pharma put US drug giant Eli Lilly under pressure for COVID-19 drug through compulsory licensing filing
The Indian company says it has offered 7% royalty to the US drugmaker for Baricitinib. Natco has filed for compulsory licensing, arguing that Eli Lilly’s small distribution network won’t be able to serve India’s population and the 14-day, Rs 42,000 per-patient treatment regimen for the US drug is too expensive.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment